{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-035987","form_type":"8-K","ticker":null,"cik":"0001403708","company_name":"Evoke Pharma Inc","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.074311+00:00","generated_at":"2026-06-04T08:24:48.777744+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Evoke Pharma amends Series B/C warrants to accelerate vesting, allow pre-funded warrants","bullets":["Series C warrants become exercisable for up to 3x Series B shares exercised before March 27, 2024 deadline.","After deadline, remaining Series B exercises trigger one-for-one vesting of Series C warrants.","Holders may elect pre-funded warrants at exercise price of $0.6799 per share instead of common stock.","No change to total number of warrant shares underlying each series.","Company will allow other holders to enter identical amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-035987","json":"https://secwatch.observer/filing/0000950170-24-035987.json","markdown":"https://secwatch.observer/filing/0000950170-24-035987.md","text":"https://secwatch.observer/filing/0000950170-24-035987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024035987/0000950170-24-035987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024035987/evok-20240325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:24:48.777744+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be38399fd768aed0f7c1ede8d11c3c1c123b2012","claim":"Evoke Pharma Inc amended Warrant Amendment with certain holders of its outstanding Series A Warrants, Series B Warrants, and Series C Warrants (effective 2024-03-25).","evidence_excerpt":"On March 25, 2024, Evoke Pharma, Inc. (the “Company”) entered into an amendment (the “Warrant Amendment”) with certain holders (each, a “Holder”) of its outstanding Series A Warrants to purchase shares of common stock (the “Series A Warrants”), Series B Warrants to purchase shares of common stock (the “Series B Warrants”), and Series C Warrants to purchase shares of common stock (the “Series C Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024035987/0000950170-24-035987-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"certain holders of its outstanding Series A Warrants, Series B Warrants, and Series C Warrants"},{"label":"Effective","value":"2024-03-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}